The highly conserved neuropeptide pituitary adenylate cyclase activating polypeptide (PACAP) has been implicated in a broad variety of physiological processes. The PACAP precursor protein gives rise to three different peptides, the cryptic peptide, GHRH, and PACAP, respectively, and here we dissect their functional properties using Xenopus as model system. PACAP and GHRH but not the cryptic peptide directly neuralize animal caps. In contrast to GHRH, the neuralizing effect mediated by PACAP is independent of the PKA pathway. Moreover, PACAP but not GHRH behaves like a BMP-4 antagonist. Blastocoel injection of PACAP-38 but not of the closely related peptides PACAP-27 and VIP leads to strong anteriorization of the injected embryos suggesting the possible involvement of a novel PACAP-preferring receptor. q
Introduction
PACAP (pituitary adenylate cyclase activating polypeptide), a highly conserved member of the vasoactive intestinal peptide (VIP)/secretin/glucagon family of regulatory peptides, has been identi®ed in a search for novel hypothalamic factors with hypophysiotropic function (Miyata et al., 1989) . It exists in two amidated forms, PACAP-38 and PACAP-27, both of which are derived from the same 175 amino acid precursor via proteolytic cleavage (Ogi et al., 1990) . PACAP-38 and PACAP-27 share the ®rst 27 amino acids exhibiting 68% homology to VIP. In addition to PACAP, two other, less conserved peptides of unknown function, the cryptic peptide and PACAP related peptide (in mammals) or a GHRH-like peptide (in non-mammalian vertebrates), respectively, are derived from the same precursor protein (McRory et al., 1995) .
The biological functions of PACAP are mediated by at least two types of G protein coupled seven transmembrane receptors. PACAP-type-II-receptors bind PACAP and VIP with equal high af®nity and lead to activation of adenylate cyclase (Hashimoto et al., 1993) . In contrast, PACAP-type-I-receptors exhibit 1000 fold higher af®nity for PACAP than for VIP and couple to different signal transduction pathways such as the PKA, the PKC, and the MAPK pathway (for review see Christophe, 1993) .
PACAP has been implicated in a broad variety of physiological processes such as regulation of pituitary function, circadian rhythmicity, learning and memory, reproductive activity, insulin secretion, and catecholamine biosynthesis (for review see Christophe, 1993; Arimura and Shioda, 1995) .
In the adult central nervous system, containing high amounts of PACAP and the PACAP speci®c type-I-receptor, PACAP is thought to act as a neurotransmitter, neuromodulator and neurotrophic factor (Arimura et al., 1994) . At day 10.5 p.c. during mouse development, PACAP expression is found in newly differentiating cells arising just outside the ventricular zone along the neural tube (Waschek et al., 1998) . This expression pattern and cell culture experiments showing PACAP induced cell cycle withdrawal and differentiation of neuronal precursor cells may implicate this peptide in brain development (Lu and DiCiccoBloom, 1997) . Moreover, the PACAP gene has been assigned to human chromosome 18p11 (Hosoya et al., 1992) , a region associated with holoprosencephaly, a disease characterized by incomplete cleavage of the forebrain, microcephaly and cyclopia (Muenke, 1994) .
Since the PACAP precursor gives rise to three different www.elsevier.com/locate/modo peptides, the cryptic peptide, GHRH and the highly conserved PACAP itself, we were interested to dissect their different functions using Xenopus as model system.
Results and discussion
As a prerequisite for our studies, we cloned the PACAP cDNA from Xenopus. On the nucleotide level, the open reading frame bears 52% overall identity with the rat cDNA; the region encoding the cryptic peptide shows 35%, the region encoding GHRH 40%, and the region encoding PACAP 88% identity with the corresponding part of the rat cDNA (Ogi et al., 1990) . The mature PACAP peptide is extremely conserved and exhibits only one amino acid exchange in position 35 (valine to isoleucine) compared with mammalian PACAP (data not shown).
We are unable to detect PACAP mRNA by in situ hybridization during Xenopus development. Using RT-PCR, PACAP expression can be detected ®rst during a short time window from MBT to the onset of gastrulation just preceding follistatin expression. At the neurula stage, PACAP expression starts together with PACAP-type-Ireceptor expression again (Fig. 1A) .
In stage 10 embryos, PACAP is ubiquitously expressed, with elevated amounts of PACAP mRNA in the vegetal cap and the dorsal marginal zone (Fig. 1B) .
To determine the possible involvement of PACAP in dorsal development, we analyzed its expression in embryos dorsalized by LiCl-treatment or ventralized by UV-irradiation. The strong upregulation of PACAP mRNA after LiCltreatment, typical for many organizer genes, suggests that PACAP may be involved in a dorso-anterior pathway (Fig.  1C) .
To get further insight into the in vivo role of PACAP in Xenopus, we injected the peptide PACAP-38 into the blastocoel. Embryos overexpressing PACAP-38 are strongly anteriorized (100% anteriorized, n 59) and show expanded heads with big cement glands (Fig. 2B,D) if compared with control embryos (Fig. 2A,C) . Conversely, overexpression of the related peptides PACAP-27 (100% normal, n 43) and VIP (97% normal, n 34) at even higher concentrations has no effect. It is known that classical PACAP-type-II-receptors bind PACAP and VIP with equal high af®nity (Hashimoto et al., 1993) . Therefore, the possibility that a PACAP-type-II-receptor mediates PACAP's actions on anterior-posterior patterning, can be ruled out. Since the normal PACAP-type-I-receptor is not expressed until the neurula stage (Fig. 1A) , it is very likely that a novel type of PACAP-preferring receptor mediates PACAP's actions during early Xenopus development. The existence of a novel, yet uncloned, PACAP-type-I-receptor subtype binding PACAP-38 but not VIP or PACAP-27 and thus exhibiting the same substrate speci®city as the receptor proposed in Xenopus has been suggested in previous studies (Zhong and Pena, 1995; Rossato et al., 1997) .
To dissect PACAP's action at the molecular level, we performed animal cap assays. Since the PACAP cDNA gives rise to three different peptides, cryptic, GHRH-like peptide, and PACAP, we used three different constructs bearing a stop signal after cryptic, the GHRH-like peptide or PACAP, respectively (Fig. 2E) . Surprisingly, not only the microinjection of full length PACAP mRNA, expressing all three peptides, but also the GHRH-like construct encom- passing the cryptic and the GHRH-like peptide neuralizes animal caps (Fig. 2F) . PACAP and the GHRH-like peptide strongly induce the neural marker NCAM and the cement gland marker XAG without inducing mesodermal markers such as actin or globin or posterior neural markers such as Xlhbox6 (Fig. 2F) . Therefore, PACAP as well as the GHRH-like peptide behave as typical direct neuralizers. In contrast, the cryptic peptide induces only slightly the cement gland marker XAG (Fig. 2F) without appearance of cement glands on the injected animal caps. Furthermore, following incubation of animal caps in solutions containing PACAP-38, PACAP-27 or VIP, only treatment with PACAP-38 leads to induction of neuronal markers (data not shown). These results underline that only PACAP-38 but not the highly related peptides PACAP-27 or VIP is the biologically active moiety.
To get further insight into the mechanisms of PACAP action and to dissect PACAP from GHRH-like peptide mediated actions, we performed ventral injections of PACAP and GHRH-like peptide mRNA in Xenopus embryos. In contrast to GHRH-like peptide, which does not yield any aberrant phenotype, PACAP behaves like a typical BMP antagonist (Fig. 3B ) and leads to development of an incomplete secondary axis (29% incomplete secondary axis, n 72). The speci®c BMP antagonistic activities of PACAP are further evidenced by rescue experiments. Embryos injected with mild doses of BMP-4 fail to develop properly, lack heads and have reduced axial structures ( Fig.  3C ; average DAI 2.0; n 38). Coinjection of PACAP together with BMP-4 rescues this phenotype ( Fig. 3D ; average DAI 5.4; n 58). In contrast to BMP-4, late Wnt overexpression ( Fig. 3E ; average DAI 2.0; n 35) cannot be rescued by PACAP and embryos remain ventroposteriorized ( Fig. 3F ; average DAI 2.1; n 29). Taken together, the upregulation of PACAP by LiCl and its direct neuralizing as well as dorsalizing effects indicate that PACAP acts as a speci®c BMP antagonist. This is further supported by changes of ventral marker gene expression. After radial RNA injections, PACAP leads to a downregulation of ventral markers such as sizzled, Wnt 8 and vent 1 while dorsal genes, such as chordin, goosecoid and otx 2 are upregulated in the ventral marginal zone of stage 11.5 embryos (Fig. 4A) . Chordin is a direct BMP-4 inhibitor that binds to BMP-4 and prevents the interaction with its receptor (Piccolo et al., 1996) . In contrast, GHRH is not able to dorsalize the ventral marginal zone, i.e. to induce dorsal markers such as chordin (Fig. 4A ), in line with the observation that GHRH does not induce an incomplete secondary axis after ventral injections.
Previous experiments have demonstrated that PACAP may act as dorsalizing factor in the neural tube since it elevates cAMP levels in cultured neuroepithelial cells and induces the downregulation of gli-1, a target gene of shh promoting ventralization (Waschek et al., 1998) . However, animal cap experiments show that PACAP does not exert its direct neuralizing and dorsalizing activity via the PKA pathway (Fig. 4B) . While induction of neuronal markers by the GHRH-like peptide is completely blocked by coinjection of transdominant-negative PKA (Clegg et al., 1987) , PACAP induced neuralization remains unaffected (Fig. 4B) . Interestingly, it has been suggested that neural induction in Xenopus embryos depends on a cross-talk between the PKA and PKC pathways (Otte et al., 1989) . The crucial step in neuralization is the activation of the PKC pathway, which leads to a direct induction of neural genes and to an enhancement of adenylate cyclase activity, which then leads to a further upregulation of neuronal genes. Without previous activation of the PKC pathway, cAMP analogues are unable to induce neuralization (Otte et al., 1989) . Since blockade of the PKA pathway blocks only GHRH but not PACAP-mediated neuralization, it is very likely, that PACAP induced neuralization is due to an activation of the PKC pathway via a PACAP-preferring PACAP-type-Ireceptor. PACAP-type-II-receptors cannot couple to the PKC pathway (for review see Christophe, 1993) In conclusion, we demonstrate that all three peptides derived from the PACAP gene exert different functions. PACAP and GHRH in contrast to the cryptic peptide have direct neuralizing activity. PACAP-induced neuralization but not GHRH-induced neuralization is independent of the PKA pathway. Our data indicate that PACAP but not GHRH is both necessary and suf®cient to antagonize BMP signalling during early Xenopus development and promote dorsoanterior cell differentiation. Overexpression of PACAP-38 in vivo leads to strong anteriorization. These data and the chromosomal localization of the human PACAP gene within a locus of holoprosencephaly raises the intriguing possibility that PACAP may be essential for anterior development in humans as well. To prove this hypothesis in Xenopus, we performed loss of function experiments (not shown). Overexpression of the speci®c PACAP antagonist PACAP 6-38 (Robberecht et al., 1992) or the extracellular ligand binding domain of the PACAP-type-I-receptor exhibiting high af®nity for PACAP (Cao et al., 1995) leads to head defects such as microcephaly and cyclopia resembling the classical symptoms of holoprosencephaly (Muenke, 1994) . But in addition, unspeci®c toxic side effects are observed and thus hamper the loss of function approach. Therefore a de®nite conclusion about the biological signi®-cance of endogenous PACAP-signalling in head development of vertebrates cannot be drawn yet.
This issue warrants further investigation, the inactivation of the PACAP gene in mouse by homologous recombination might be a suitable approach.
Experimental procedures

Embryos and explants
In vitro fertilization, embryo culture, staging, microinjection, culture of explants, and treatment with LiCl and UV were performed as described (Gawantka et al., 1995) . For peptide injections in the blastocoel, PACAP-38 (same for human, mice, and rat), PACAP-27, and VIP were purchased from Bachem and dissolved in water containing acetylated BSA (1 mg/ml) as carrier. Embryos were injected at stage 8 with 1.3 pmol PACAP-38, 6.6 pmol of each, PACAP-27 and VIP or carrier solution.
Cloning of Xenopus PACAP cDNA
Using degenerated primers, a 114 bp fragment, coding for the mature PACAP peptide, was obtained by RT-PCR from Xenopus brain cDNA. This fragment was extended to a 450 bp fragment by 3 H -RACE. With this sequence information two primers were designed and used for screening a Xenopus stage 31 head library (A. Glinka, unpublished) . The cDNA sequence obtained from the PACAP-positive clone is identical with the recently published sequence for Xenopus PACAP (EMBL accession no. AF 187877).
Constructs
In order to obtain templates for the in vitro transcription of PACAP, GHRH, and CRY cDNA, DNA fragments terminating with a stop codon after CRY, GHRH or PACAP were PCR-ampli®ed from PACAP cDNA. In all three cases, the following forward primer was used: CCCGAATTCAAGA-CAATGTGTAGGAAAGCGC (EcoRI site and starting ATG in bold). The following reverse primers were used: PACAP, CCCCTCGAGCTACAAATATGCTACACGC-CGT (XhoI site in bold); GHRH, CCCCTCGAGC-TACCGTTTAGATAAGGGTTCC (XhoI site in bold); CRY, CCCCTCGAGCTATCTCTTTTCCGGCGGGTAA-TAA (XhoI site in bold). The PCR-ampli®ed fragments were digested with EcoRI and XhoI and subcloned into pCS21 (Rupp et al., 1994) . PCR ampli®cations were carried out using the Expande High Fidelity kit (Roche), the subcloned fragments were sequenced on both strands.
For microinjection of mRNA, the ORF of mouse as well as Xenopus PACAP was subcloned in pCS21 (Rupp et al., 1994) , linearized with NotI and transcribed with SP6 polymerase using the Ambion kit. In all injections, mouse and Xenopus PACAP mRNA have identical effects.
Other constructs used for in vitro transcription were: dnPKA (Clegg et al., 1987) , tBR (Suzuki et al., 1994) , pCSKA-Wnt (Christian and Moon, 1993) , BMP-4 (Fainsod et al., 1994) , and PPL (Glinka et al., 1996) .
RT-PCR
PCR assays with reverse transcription (RT-PCR) were carried out in the exponential phase of ampli®cation as described (Gawantka et al., 1995) . PCR primers used were actin (Niehrs et al., 1994) , goosecoid (Glinka et al., 1996) , histone H 4 (Glinka et al., 1996) , XAG (Gammil and Sive, 1996) , otx-2 (Glinka et al., 1997) , siamois (f: AAACCACT-GATTCAGGCAGAGG; r: GTAGGGCTGTGTATTTGA-AGGG), globin (Banville and Williams, 1985) , NCAM (Blitz and Cho, 1995) , chordin (Glinka et al., 1996) , PACAP (f: TTCACCGACAGCTACAGTCG; r: TGTT-TGTAGATAACACAGGAGC), PACAP-type-I-receptor (P-I-R, f: GGGCTTTATCTCTTTACGCTCC; r: ATTATT-GATCCAATAACAGGACCC), vent 1 (Gawantka et al., 1995) , Wnt 8 (Gawantka et al., 1995) , Xnr 3 (Smith et al., 1995) , keratin (Wilson and Hemmati-Brivanlou, 1995), Xlhbox 6 (Hemmati-Brivanlou and , sizzled (f: CCT GCC GTA GTA TGT GTG TAG C; r: TGT TTA ATG AAC TCA ACT GGG C), follistatin (HemmatiBrivanlou et al., 1994) and noggin (Smith and Harland, 1992) . Fig. 4 . PACAP has dorsalizing and neuralizing activity that is not dependent on the PKA pathway. (A) VMZ assay: 4-cell embryos were radially microinjected into all blastomeres. The ®nal doses of mRNA per blastomere were 0.5 ng preprolactin (PPL), CRY, GHRH, and PACAP or 0.25 ng of transdominant-negative BMP-4 receptor (tBR) mRNA. In addition, stage 8 embryos were injected with 1.3 pmol PACAP-38 peptide in the blastocoel. Dorsal (DMZ) or ventral marginal zone (VMZ) fragments were cut from early gastrulae and analyzed at stage 11.5 by r-PCR for marker gene expression. 2RT (minus reverse transcription control sample). Note, that PACAP, but not GHRH or CRY dorsalizes ventral marginal zones. (B) Animal cap assay: 4-cell embryos were microinjected into the animal region of all blastomeres. The ®nal dose of mRNA per blastomere were 0.5 ng PACAP, dominant-negative PKA (dnPKA), and GHRH mRNA alone or in combination as indicated. Animal cap fragments were cut from late blastulae, cultured until stage 31 and analyzed by RT-PCR for the expression of marker genes as indicated. Co, animal cap from uninjected embryo; E, untreated control embryo; 2RT, minus reverse transcription control sample.
